EUCTR2015-000820-27-ES进行中（未招募）不适用
Double blind, placebo-controlled, dose finding, prospective, multicenter clinical trial for the treatment of rhinitis/rinoconjuntivitis against a mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extract
Inmunotek, S.L.0 个研究点目标入组 180 人开始时间: 2015年9月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent
- •- Positive suggestive clinical history of intermittent or persistent moderate to severe rhinitis /rhinoconjunctivitis, with or without moderate asthma, due to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae
- •- Subjects with a positive skin prick-test (wheal sixe >6 mm diameter) to a Dermatophagoides pteronyssinus and/or Dermatophagoides farinae allergen extract
- •- Specific IgE against house dust mites >10 kU/L and and whose determination does not exceed 6 months prior to the inclusion visit
- •- Age between 12 and 65 years
- •- Both genders
- •- Subjects capable of giving informed consent
- •- Subjects capable of complying with the dosing regimen
- •- Subjects that have not received immunotherapy against mites in the last 5 years
- •- Subjects submitting sensitization to other aeroallergens, but is considered clinically irrelevant or without clinical interference with the nasal provocation test.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 40
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 140
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Subjects outside of the age range.
- •- Subjects who have previously received immunotherapy for the treatment of the allergic rhinitis/rhinoconjunctivitis due to mites and other allergens in the last 5 years.
- •- Subjects that immunotherapy may be an absolute contraindication according to the criteria of the immunotherapy Committee of the Spanish society of Allergy and Clinical Immunology, and of the European Allergy and Clinical Immunology Immunotherapy Subcommittee may also include.
- •- Subjects with important symptoms of rhinoconjunctivitis in which the suspension of the systemic antihistamine treatment is contraindicated.
- •- Subjects with persistent severe or not controlled asthma, with a FEV< 70 respect to the reference value in spite of the appropriate pharmacological treatment at the time of the inclusion in the trial.
- •- Subjects that have required oral corticosteroids in the 12 weeks previous to the inclusion in the trial.
- •- Subjects who receive or have received omalizumab
- •- Subjects who can not stop treatment with intranasal corticosteroids
- •- Subjects with persistent asthma treated with inhaled intranasal corticosteroids
- •- Subjects treated with angiotensin converting enzyme inhibitors ( ACEIs )
- •- Subjects that have some pathology (hyperthyroidism, hypertension, heart disease, etc.) in which immunotherapy is contraindicated.
- •- Subjects in treatment with beta blockers.
- •- Subjects that have previously submitted a serious secondary reaction during the skin prick test
- •- Subject with active chronic urticaria in the last 2 years
- •- Subjects with hereditary angioedema.
- •- Subjects with any other disease not associated with the rhinitis/rhinoconjunctivitis, but of potential severity and that could interfere with treatment and follow-up (epilepsy, psychomotor deterioration, malformations, kidney diseases,...).
- •- Subjects with tumor diseases
- •- Subject diagnosed or diagnosed with immunodeficiencies
- •- Subjects with chronic sinusitis
- •- Subjects with acute otitis media
- •- Subjects with active positive dermographism
- •- Subjects with structural alterations of the nasal fossa ( polyps , deviated septum, turbinate hypertrophy, not alterable nasal obstruction, nasal vasoconstriction , etc
- •- Subject whose status prevents him from providing cooperation and or which present severe psychiatric disorders.
- •- Subject with known allergy to other components of the vaccine different from mites allergen extract.
- •- Subjects with lower airway diseases other than asthma such as emphysema or bronchiectasis.
- •- Direct investigator's relatives
- •- Pregnant or women at risk of pregnancy and breastfeeding women.
研究者
相似试验
进行中（未招募）
不适用
Double blind, placebo-controlled, dose finding, prospective, multicenter clinical trial for the treatment of rhinitis/rinoconjuntivitis against grass pollen allergyGrass pollen allergyMedDRA version: 18.0Level: LLTClassification code 10036019Term: Pollen allergySystem Organ Class: 100000004870EUCTR2014-005471-88-ESINMUNOTEK, S.L.180
未知
2 期
ate phase II study of ME3113Benign prostatic hyperplasia with lower urinary tract symptomsJPRN-jRCT2080221911Meiji Seika Pharma Co., Ltd.800
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.EUCTR2005-005975-13-EEPIERRE FABRE MEDICAMENT600
进行中（未招募）
1 期
Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.Seasonnal Allergic rhinitis Prospective, multicentric, international, randomised, double-blind trial in six parallel groups: 4 doses of the test product, active control and placebo. This study is intended to evaluate the efficacy and a dose response of V0114 (l-MEQUITAZINE) in a clinical situation with patients having a hay fever.EUCTR2005-005975-13-FRPIERRE FABRE MEDICAMENT600
进行中（未招募）
1 期
Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.Prospective, multicentric, international, randomised, double-blind trial in six parallel groups: 4 doses of the test product, active control and placebo. This study is intended to evaluate the efficacy and a dose response of V0114 (l-MEQUITAZINE) in a clinical situation with patients having a hay fever.EUCTR2005-005975-13-CZPIERRE FABRE MEDICAMENT600